We are live on ! Find out more
BC

Birchview Capital Portfolio holdings

AUM $176M
1-Year Est. Return 95.04%
This Fund
S&P 500
This Quarter Est. Return
-15.07%
1 Year Est. Return
+95.04%
3 Year Est. Return
+233.14%
5 Year Est. Return
+280.2%
10 Year Est. Return
+1,023.63%
AUM
$113M
AUM Growth
-$24.8M
Cap. Flow
+$8.66M
Cap. Flow %
7.68%
Top 10 Hldgs %
80.31%
Holding
57
New
5
Increased
11
Reduced
3
Closed
11

Top Buys

Rank Stock Value
1
ACAD icon
Acadia Pharmaceuticals
ACAD
+$3.21M
2
AMRN
Amarin Corp
AMRN
+$2.01M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$1.86M
4
BIIB icon
Biogen
BIIB
+$1.82M
5
GILD icon
Gilead Sciences
GILD
+$1.38M

Top Sells

Rank Stock Value
1
DERM
Dermira, Inc.
DERM
+$1.21M
2
WMGI
Wright Medical Group Inc
WMGI
+$914K
3
SLNO
Soleno Therapeutics
SLNO
+$877K
4
MYGN icon
Myriad Genetics
MYGN
+$817K
5
ARVN icon
Arvinas
ARVN
+$702K

Sector Composition

Rank Sector Weight
1 Healthcare 95.51%
2 Energy 0.77%
3 Consumer Staples 0.06%
4 Consumer Discretionary 0.04%
5 Materials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CORT icon
26
Corcept Therapeutics
CORT
$10.2B
$594K 0.53%
50,000
– –
ODT
27
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
$552K 0.49%
20,000
– –
ICPT
28
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$523K 0.46%
8,300
– –
SLNO
29
DELISTED
Soleno Therapeutics
SLNO
$480K 0.43%
13,433
-20,607
-61% -$877K
STOK icon
30
Stoke Therapeutics
STOK
$1.82B
$458K 0.41%
+20,000
New +$494K
GTHX
31
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$441K 0.39%
40,000
– –
IFRX icon
32
InflaRx
IFRX
$256M
$420K 0.37%
+110,000
New +$407K
XNCR icon
33
Xencor
XNCR
$1.44B
$368K 0.33%
12,300
– –
FOLD
34
DELISTED
Amicus Therapeutics
FOLD
$351K 0.31%
38,000
– –
BHVN
35
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$340K 0.3%
10,000
– –
PGNY icon
36
Progyny
PGNY
$2.44B
$318K 0.28%
15,000
– –
TBIO
37
DELISTED
Translate Bio, Inc. Common Stock
TBIO
$299K 0.27%
+30,000
New +$246K
VYGR icon
38
Voyager Therapeutics
VYGR
$187M
$274K 0.24%
30,000
– –
PXD
39
DELISTED
Pioneer Natural Resource Co.
PXD
$267K 0.24%
3,800
– –
KALV
40
DELISTED
KalVista Pharmaceuticals
KALV
$230K 0.2%
30,000
– –
APLS
41
DELISTED
Apellis Pharmaceuticals
APLS
$214K 0.19%
8,000
– –
DRNA
42
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$184K 0.16%
10,000
– –
TGTX icon
43
TG Therapeutics
TGTX
$8.58B
$148K 0.13%
15,000
– –
YTEN
44
DELISTED
Yield10 Bioscience, Inc. Common Stock
YTEN
$71K 0.06%
790
– –
WKHS icon
45
Workhorse Group
WKHS
$29.5M
$45K 0.04%
8
– –
BCRX icon
46
BioCryst Pharmaceuticals
BCRX
$2.37B
$40K 0.04%
20,000
– –
GOSS icon
47
Gossamer Bio
GOSS
$66.5M
– –
-30,000
Closed -$469K
LXRX icon
48
Lexicon Pharmaceuticals
LXRX
$1.02B
– –
-80,000
Closed -$332K
MYGN icon
49
Myriad Genetics
MYGN
$530M
– –
-30,000
Closed -$817K
OVV icon
50
Ovintiv
OVV
$17.5B
– –
-9,910
Closed -$232K
1
2
3

Similar funds

RWA
Resolute Wealth Advisor Findlay, Ohio $176M AUM
BAM
Boyar Asset Management New York $176M AUM 20.04% 1-Year Est. Return
TIM
Tevis Investment Management Plano, Texas $176M AUM 18.14% 1-Year Est. Return
LWM
Lifetime Wealth Management Rockwall, Texas $176M AUM
PFA
Providence Financial Advisors Overland Park, Kansas $175M AUM
DAM
Draper Asset Management Smithtown, New York $176M AUM 37.45% 1-Year Est. Return
AF
Align Financial Hermantown, Minnesota $176M AUM
OA
Oceanside Advisors Mount Pleasant, South Carolina $175M AUM 17.96% 1-Year Est. Return

Birchview Capital's Q1 2020 Portfolio in Review

As of Q1 2020, Birchview Capital held 57 positions worth $113M, down 18% from $138M the previous quarter. Its ten largest holdings account for 80% of the portfolio.

Birchview Capital deployed $8.66M of net new capital in Q1 2020, opening 5 new positions and adding to 11 existing holdings. Its largest new stake was Gilead Sciences: 20,000 shares worth $1.5M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 95% a quarter earlier, followed by Energy and Consumer Staples.

On the sell side, the largest reduction was Soleno Therapeutics, an estimated $877K trimmed.

  • Birchview Capital's largest Q1 2020 buy was Gilead Sciences: 20,000 shares worth $1.5M.
  • Birchview Capital added most to Acadia Pharmaceuticals in Q1 2020, an estimated $3.21M increase.
  • Birchview Capital's biggest Q1 2020 reduction was Soleno Therapeutics, cutting an estimated $877K.
  • Birchview Capital fully exited Dermira, Inc. in Q1 2020, selling an estimated $1.21M.
  • Birchview Capital's ten largest holdings make up 80% of its $113M portfolio in Q1 2020.
  • Birchview Capital opened 5 new positions and closed 11 in Q1 2020.
  • Birchview Capital's portfolio value fell 18% quarter-over-quarter to $113M.

Based on Birchview Capital's 13F filing for Q1 2020, filed 12 May 2020.